100-35-6

Basic information

• Product Name: (2-CHLORO-ETHYL)-DIETHYL-AMINE
• Synonyms: N-(2-CHLORO ETHYL)DIETHYLAMINE;2-(DIETHYLAMINO)ETHYL CHLORIDE;(2-CHLORO-ETHYL)-DIETHYL-AMINE;AURORA KA-7583;2-(diethylamino)chloroethane;2-chloro-triethylamin;2-chlorotriethylamine;beta-(diethylamino)ethylchloride
• CAS NO: 100-35-6
• Molecular Formula: C₆H₁₄ClN
• Molecular Weight: 135.64
• EINECS: 202-843-1
• Mol File: 100-35-6.mol
• Article Data: 15

Chemical Properties

• Melting Point: 173-175 °C
• Boiling Point: 219.31°C (rough estimate)
• Flash Point: 22.8°C
• Appearance: /
• Density: 1.0013 (rough estimate)
• Vapor Pressure: 20.3mmHg at 25°C
• Refractive Index: 1.4530 (estimate)
• PKA: 9.37±0.25(Predicted)
• CAS DataBase Reference: (2-CHLORO-ETHYL)-DIETHYL-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (2-CHLORO-ETHYL)-DIETHYL-AMINE(100-35-6)
• EPA Substance Registry System: (2-CHLORO-ETHYL)-DIETHYL-AMINE(100-35-6)

Safety Data

• Hazardous Substances Data: 100-35-6(Hazardous Substances Data)

Usage

Carcinogenicity

No studies to assess carcinogenic potential were found. In addition, this chemical has not been evaluated for carcinogenicity potential by the IARC or ACGIH. However, its dimethyl analog produced lung tumors in strain A mice following intraperitoneal injection.

InChI:InChI=1/C6H14ClN.H2O4S/c1-3-8(4-2)6-5-7;1-5(2,3)4/h3-6H2,1-2H3;(H2,1,2,3,4)

Upstream product

• 14426-20-1 N,N-diethylethanolammonium chloride 
• 2210-36-8 diethylaziridinium chloride 
• 869-24-9 2-chloro-N,N-diethylethylamine hydrochloride 
• 100-37-8 2-(Diethylamino)ethanol 

Downstream Products

• 6312-05-6 diethyl-(3-[2]pyridyl-propyl)-amine 
• 72395-46-1 1-(2-diethylamino-ethyl)-indole 
• 785712-86-9 1-(2-diethylamino-ethyl)-hexahydro-azepine 
• 95800-24-1 1-[3-(2-diethylamino-ethoxy)-phenyl]-2,5-dimethyl-pyrrole 
• 76-65-3 3-(2-diethylamino-ethyl)-3-phenyl-3H-benzofuran-2-one 
• 94915-46-5 4-(N,N-diethylamino)-2-phenyl-2-(2-pyridyl)butanenitrile 
• 107923-94-4 N,N-diethyl-N'-(4,6-dimethyl-pyrimidin-2-yl)-N'-phenyl-ethylenediamine 
• 860672-31-7 1-[2-(diethylamino)ethyl]-3-phenylquinoxalin-2(1H)-one 
• 93999-62-3 4-(4-diethylamino-2-phenyl-butyryl)-morpholine 
• 24539-72-8 N,N-diethylaminoethyl xanthene-9-carboxylate 
• 53230-07-2 cyclopent-2-enyl-[2]thienyl-acetic acid-(2-diethylamino-ethyl ester) 
• 101864-94-2 2-phenyl-5,6-dihydro-4H-pyran-3-carboxylic acid-(2-diethylamino-ethyl ester) 
• 853992-73-1 cyclohex-2-enyl-[2]thienyl-acetic acid-(2-diethylamino-ethyl ester) 
• 103034-56-6 1,3-bis-(2-diethylamino-ethyl)-5-ethyl-5-phenyl-pyrimidine-2,4,6-trione 

Relevant articles and documents

Understanding the Alkylation Mechanism of 3-Chloropiperidines – NMR Kinetic Studies and Isolation of Bicyclic Aziridinium Ions

The present study describes the kinetic analysis of the 3-chloropiperidine alkylation mechanism. These nitrogen mustard-based compounds are expected to react via a highly electrophilic bicyclic aziridinium ion, which is readily attacked by nucleophiles. Halide abstraction using silver salts with weakly coordinating anions lead to the isolation of these proposed intermediates, whereas their structure was confirmed by single crystal XRD. Kinetic studies of the aziridinium ions also revealed notable reactivity differences of the C5 gem-methylated compounds and their unmethylated counterparts. The observed reactivity trends were also reflected by NMR studies in aqueous solution and DNA alkylation experiments of the related 3-chloropiperidines. Therefore, the underlying Thorpe-Ingold effect might be considered as another option to adjust the alkylation activity of these compounds.

Design, Synthesis, and Biological Evaluation of Scutellarein Derivatives Based on Scutellarin Metabolic Mechanism in Vivo

Three series of scutellarein derivatives have been designed and synthesized based on metabolic mechanism of scutellarin (1) in vivo. Their thrombin inhibition activities were tested through the analyzation of prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen (FIB). The antioxidant activities of these target products were assessed by 1,1-diphenyl-2-picrylhydrazyl radical (DPPH) assay and the ability to protect PC12 cells against H2O2-induced cytotoxicity, and their solubilities were evaluated by ultraviolet (UV) spectrophotometer. The results showed that the two isopropyl groups substituted derivative (18c) demonstrated stronger anticoagulant activity, better water solubility, and good antioxidant activity compared with scutellarein (2), which warrants further development of 18c as a promising agent for ischemic cerebrovascular disease treatment. Three series of scutellarein derivatives have been designed and synthesized based on metabolic mechanism of scutellarin (1) in vivo. The results of the biological evaluation showed that the two isopropyl groups substituted derivative (18c) demonstrated stronger anticoagulant activity, better water solubility, and good antioxidant activity compared with scutellarein (2), which warrants further development of 18c as a promising agent for ischemic cerebrovascular disease treatment.

Receptor ligands

Use of a compound selected from the group consisting of 3,5-diiodo-4-(2-N, N-diethylaminoethoxy)phenyl-(2-butylbenzofur-3-yl)methanol hydrochloride (001), 2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylaminoethoxy)-benzoyl)benzofuran hydrochloride (003), 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)benzofuran (005), 2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran (011), 2-methyl-3-(3,5-diiodo-4-carboxymethoxybenzyl)benzofuran (015), 4'-hydroxy-3'-iodo-3,5-diiodo-4-(2-N,N-diethylaminoethoxy)benzophenon hydrochloride (024), 2-butyl-3-(3-iodo-4-hydroxy-benzoyl)benzofuran (029), 4'4'-dihydroxy-3'3,5-triiododiphenylmethan (032), which compound is a 3,5,3'-triiodothyronine (T-3) receptor ligand, for the preparation of a medicament for the therapeutic or prophylactic treatment of a disorder which depends on the expression of T-3 regulated genes, and pharmaceutical preparations comprising said compounds, are disclosed. Further, a method of prophylactically or therapeutically treating a patient having a disorder which depends on the expression of 3,5,3"-triiodo-thyronine (T-3) regulated genes is also disclosed. The invention additionally comprises product protection for all the above listed compounds, except the compound (011).